Analyst RecommendationOnKure Therapeutics, Inc. received a 'Buy' rating from analysts.
Clinical TrialsNo dose-limiting toxicities have been observed in the OKI-219 + fulvestrant combination, with OnKure nearing the end of the dose escalation.
Drug DevelopmentThe treatment landscape for HR+/HER2- breast cancer is evolving swiftly, potentially benefiting OnKure's strategic approach with OKI-219.